After discussions with the FDA, Oncopeptides AB has initiated the preparation for submitting a New Drug Application for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma.
Last week’s issue of The Cancer Letter included an obituary that the entire staff at The Cancer Letter had been dreading for years: Abdallah Abou Zahr, an oncologist at Roger Maris Cancer Center in Fargo, ND, died Jan. 23 of a liposarcoma after a five-year battle with the disease.
